Targeting EGFR With Indole Derivatives: Recent Advances and Therapeutic Perspectives

Area of Science:

• Medicinal Chemistry
• Oncology
• Drug Discovery

Background:

• Epidermal Growth Factor Receptor (EGFR) inhibitors are crucial in cancer therapy but face challenges with drug resistance and toxicity.
• Indole scaffolds offer a promising alternative due to their structural versatility, favorable pharmacokinetics, and ability to bind to the EGFR ATP-binding pocket.

Purpose of the Study:

• To review recent literature (2021-2025) on indole-based Epidermal Growth Factor Receptor (EGFR) inhibitors.
• To highlight the potential of indole scaffolds in developing next-generation targeted cancer therapies that overcome resistance and reduce side effects.

Main Methods:

• Literature review of studies published between 2021 and 2025.
• Analysis of mechanistic insights, biological screening data, and therapeutic potential of indole EGFR inhibitors.
• Consideration of advances in molecular docking, structure-activity relationship (SAR) studies, and hybrid drug design.

Main Results:

• Indole derivatives effectively inhibit EGFR auto-phosphorylation, blocking cancer cell proliferation, survival, and metastasis.
• The clinical success of indole-based EGFR inhibitors, such as osimertinib, validates their therapeutic potential.
• Recent research indicates that indole scaffolds can be optimized to address resistance mutations and minimize adverse effects.

Conclusions:

• Indole scaffolds represent a valuable starting point for designing novel, potent, and selective EGFR inhibitors.
• Further development of indole-based compounds holds significant promise for advancing targeted cancer therapy and improving patient outcomes.